The performance of Edwards Lifesciences Corporation (EW) seems to be under scrutiny recently. In spite of outperforming competitors on strong trading days, there have been reductions in next year's estimates and drops in Revenue and Earnings per share. The company's stock fluctuated with a decrease on certain days and also an executive sold shares worth over $333,000. Interestingly, EW sees an increase in volume.
BD has plans to acquire EW's Critical Care Product Group for $4.2 Billion, expanding its Advanced Monitoring Technology. There are uncleared speculations over the growth opportunities of EW. Despite a disappointing 43% loss over the past three years, it managed a favorable 42% return over the past five years. Edwards Lifesciences deals with debt adequately and seems to have strong fundamentals.
There have been mixed results in the quarterly earnings with margins dipping in Q2, but a tone of optimism prevails over the future stock performance. Strikingly, EW makes a strategic purchase of Innovalve. Even with a lower price target by Truist Financial, EW resolutely maintains its 'Outperform' Rating. The company's financial results for Q4 and Full-Year 2023 are robust and it plans two more M&A deals. Edwards Lifesciences Corp. remains determinedly focused on the heart.
Edwards Lifesciences Corp EW News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sat, 14 Sep 2024 01:37:42 GMT - Rating -2 - Innovation 1 - Information 4 - Rumor -3
